This free survey is powered by
Create a Survey
Surveys
2015
March
A
ALAI - ATI
ALAI - ATI
0%
Exit Survey
ACCOUNT MANAGER NAME
-- Select --
Name 1
Name 2
Name 3
Name 4
Name 5
Name 6
Name 7
Name 8
Name 9
Name 10
Name 11
Name 12
Name 13
Name 14
Name 15
Name 16
Name 17
Name 18
Name 19
Name 20
Name 21
Name 22
Name 23
Other
ACCOUNT
-- Select --
AETNA US HEALTHCARE
BCBS AR
BCBS AZ
BS OF CA
CAPITAL BC PA CENTRAL
CVS HEALTH
CATAMARAN CORPORATION
Magellan
CIGNA HEALTHCARE
EMBLEMHEALTH
EXPRESS SCRIPTS
GATEWAY HEALTH PLAN
HEALTH ALLIANCE MEDICAL PLANS HAMP
HARVARD PILGRIM HEALTHCARE
HEALTHPARTNERS
HEALTH NET
HIGHMARK BCBS
HORIZON BCBS NJ
HUMANA HEALTH PLAN
Magellan
INDEPENDENT HEALTH
MVP HEALTH CARE PREFERRED CARE
NAVITUS HEALTH SOLUTIONS
OPTUMRX
CONTRA COSTA HEALTH PLAN
PHYSICIANS PLUS INSURANCE
PRESBYTERIAN HEALTH PLAN
PRIME THERAPEUTICS
CAMBIA HEALTH SOLUTIONS
BAYLOR SCOTT & WHITE HEALTH
SELECTHEALTH
SENTARA HEALTH SYSTEM
UNITED
UNITY HEALTH PLANS
UPMC HEALTH PLAN
Has this account changed their management approach to the APS/ALAI category in the last 12 months? (SELECT ANY THAT APPLY
Oral APS
ALAI
Yes - Increase branded product access (added to preferred listing)
Yes - Increase branded product access (reduced restrictions/barriers)
Yes - Limit branded product access (reduced preferred listing)
Yes - Limit branded product access (Increased restrictions/barriers)
No - They have not made any changes
Don’t know
MANAGEMENT OBJECTIVES: The plan has expressed their current management objectives for the antipsychotic oral and LAI I market as: (SELECT ANY THAT APPLY)
Oral APS
ALAI
Ensure “appropriate use” of oral generics
Limit usage to certain diagnosis (limit to SZ)
Influence product selection (drive usage to preferred branded products)
Limit the overall use of the products in the category
Identify patients and providers for case management efforts
Management objectives are not known
Is the account likely to change their management approach in the APS/ALAI category in the next 12 months? (SELECT ANY THAT APPLY)
Oral APS
ALAI
Yes - Increase branded product access (added to preferred listing)
Yes - Increase branded product access (reduced restrictions/barriers)
Yes - Limit branded product access (reduced preferred listing)
Yes - Limit branded product access (Increased restrictions/barriers)
No - They are not likely to make any changes
Don’t know
For a newly approved drug, in a protected class, what type of coverage will be assigned prior to a P&T review and a formulary action? (ALL THAT APPLY)
Not covered (NDC block)
Covered with Non-preferred Tier status
Covered after Step therapy with formulary listed products
Covered after Prior Authorization or medical exception
For a newly approved drug, in a protected class, are they likely to conduct a review for the individual product or the entire category?
Individual product review
Category review
Don’t know
For a newly approved drug, in a protected class, when will are they likely to conduct a review for the category/product?
Medicare
Medicaid
Commercial
Est. Review Month (MM/YY)
For a newly approved drug, in a protected class, when will are they likely to conduct a review for the category/product? (Please select the approximate month)
-- Select --
10/15
11/15
12/15
1/16
2/16
3/16
4/16
5/16
6/16
7/16
8/16
9/16
10/16
11/16
12/16
1/17
2/17
3/17
4/17
Please select the option which best characterizes any unsolicited comments the customer has volunteered related to the importance of the category to in terms of their priorities.
Very unimportant
Somewhat unimportant
Neutral
Somewhat Important
Very Important
Do not know
Management Priority
Loading...
close
Loading...
Close
qprun1.questionpro.net